药学监护对终末期肾病血液透析伴高血压患者降压效果观察

Efficacy Observation on Antihypertensive Effect of Pharmaceutical Care on Patients with End- stage Renal Disease Hemodialysis Combining with High Blood Pressure

目的:临床药师通过药学监护建立与血液透析患者的联系,与医师共同选择个体化降压治疗方案,降低患者的高血压,提高血液透析患者的生命质量。方法:选取我院符合纳入标准的血液透析伴高血压患者,随机分为药学监护组(20例)与非药学监护组(21例)。结果:治疗3个月后,药学监护组患者收缩压158mmHg下降至139mmHg,舒张压95mmHg下降至84mmHg,非药学监护组患者收缩压155mmHg下降至152mmHg,舒张压96mmHg下降至93mmHg,药学监护组与非药学监护组比较差异有统计学意义(P<0.05)。结论:通过药学监护,临床药师参与终末期肾病血液透析伴高血压患者个体化降压治疗,可促进医疗质量的提高。

OBJECTIVE：To establish the relationship of clinical pharmacist with hemodialysis patients through pharmaceutical care and select individualized therapeutic regime by pharmacists and physicians in order to reduce high blood pressure and improve quality of life in hemodialysis patients. METHODS：Hemodialysis patients with hypertension being in line with included cretria were collected and randomly divided into pharmaceutical care group（n=20） and non-pharmaceutical care group（n=21）. RESULTS：After 3 months of treatment,in pharmaceutical care group SBP was decreased from 158 mmHg to 139 mmHg and DBP from 95 mmHg to 84 mmHg;in non-pharmaceutical care group SBP was decreased from 155 mmHg to 152 mmHg and DBP from 96 mmHg to 93 mmHg. There was significant difference between pharmaceutical care group and non- pharmaceutical care group （P0.05）. CONCLUSION：Clinical pharmacist participating in individualized antihypertensive treatment for end-stage renal disease hemodialysis patients with high blood pressure through pharmaceutical care can improve quality of healthy care.